[1]周 芳,陈文明,陈新宇,等.冬春谧阳方对高脂血症患者PPARγ/ANGPTL受体配体的影响[J].陕西中医,2023,(11):1537-1541.[doi:DOI:10.3969/j.issn.1000-7369.2023.11.009]
　ZHOU Fang,CHEN Wenming,CHEN Xinyu,et al.Effect of Dongchun Miyang decoction on serum PPARγ/ANGPTL receptor ligand in patients with hyperlipidemia[J].,2023,(11):1537-1541.[doi:DOI:10.3969/j.issn.1000-7369.2023.11.009]
点击复制

冬春谧阳方对高脂血症患者PPARγ/ANGPTL受体配体的影响
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2023年11期
页码:
1537-1541
栏目:
临床研究
出版日期:
2023-11-05

文章信息/Info

Title:
Effect of Dongchun Miyang decoction on serum PPARγ/ANGPTL receptor ligand in patients with hyperlipidemia
作者:
周 芳; 陈文明; 陈新宇; 蔡嘉洛; LAU Yutong(新加坡)
(湖南中医药大学第一附属医院,湖南 长沙 410007)
Author(s):
ZHOU Fang; CHEN Wenming; CHEN Xinyu; CAI Jialuo; LAU Yutong
(The First Hospital of Hunan University of Chinese Medicine,Changsha 410007,China)
关键词:
高脂血症;  痰浊阻遏证;  冬春谧阳方;  血管生成素样蛋白;  过氧化物酶体增殖物激活受体γ;  血脂;  肝肾功能
Keywords:
Hyperlipidemia;  Tanzhuo Zu'e syndrome;  Dongchun Miyang prescription;  Angiopoietin-like proteins;  Peroxisome proliferator-activated receptor γ;  Blood lipids;  Liver and kidney function
分类号:
R 714.252
DOI:
DOI:10.3969/j.issn.1000-7369.2023.11.009
文献标志码:
A
摘要:
目的:探讨冬春谧阳方对高脂血症患者血清过氧化物酶体增殖物激活受体γ/血管生成素样蛋白(PPARγ/ANGPTL)受体配体水平的影响。方法:按随机数字表法将80例高脂血症患者分入两组。对照组给予辛伐他汀治疗,治疗组给予辛伐他汀联合冬春谧阳方治疗。比较两组治疗前后中医症状评分、血脂四项、肝肾功能指标、ANGPTL4、ANGPTL3、PPARγ水平及其疗效、不良反应。结果:治疗组的总有效率95.00%高于对照组的72.50%(χ2=7.44,P=0.006)。治疗后,两组痰浊阻遏证候各评分均降低,且治疗组的形体肥胖、呕恶痰涎、胸胁胀闷、心烦不安评分低于对照组(均P<0.05)。治疗后,两组TC、TG、LDL-C均降低,HDL-C升高,且治疗组TC、TG、LDL-C低于对照组,而HDL-C高于对照组(均P<0.05)。治疗后,两组ANGPTL4、ANGPTL3降低,PPARγ升高,且治疗组ANGPTL4、ANGPTL3低于对照组,而PPARγ高于对照组(均P<0.05)。治疗后,对照组肝肾功能指标低于治疗组(均P<0.05)。治疗组不良反应发生率5.00%低于对照组25.00%(χ2=6.28,P=0.01)。结论:冬春谧阳方治疗高脂血症疗效较好,能改善患者临床症状,降低血脂,且更安全,其机制可能与改善血清PPARγ/ANGPTL受体配体有关。
Abstract:
Objective:To explore effect of Dongchun Miyang decoction on serum levels of peroxisome proliferator-activated receptor γ/angiopoietin-like protein(PPARγ/ANGPTL)receptor ligands in patients with hyperlipidemia.Methods:Eighty patients with hyperlipidemia divided into two groups according to random number table method.The control group received simvastatin treatment,and the treatment group received simvastatin combined with Dongchun Miyang prescription treatment.Chinese medicine symptom score,four items of blood lipid,liver and kidney function indexes,ANGPTL4,ANGPTL3,PPARγ levels before and after treatment were compared between the two groups,effects and adverse reactions analyzed.Results:The total effective rate of the treatment group 95.00% was significantly higher than that in the control group 72.50%(χ2=7.44,P=0.006).After treatment,the scores of sputum turbidity repressing syndrome in both groups were decreased,and the scores of body obesity,vomiting,phlegm salivation,chest and stomach distension,upset in the treatment group were lower than those in the control group(all P<0.05).After treatment,the levels of TC,TG and LDL-C were decreased and HDL-C increased,while the levels of TC,TG and LDL-C were lower and the level of HDL-C higher in the treatment group than those in the control group(all P<0.05).After treatment,the levels of ANGPTL4 and ANGPTL3 were decreased and the levels of PPARγ were increased,and the levels of ANGPTL4 and ANGPTL3 were lower while the levels of PPARγ higher in the treatment group than those in the control group(all P<0.05).After treatment,the decrease of liver and kidney function in the control group were lower than those in the treatment group(all P<0.05).The rate of side reactions in treatment group 5.00% was lower than that in the control group 25.00%(χ2=6.28,P=0.01).Conclusion:Dongchun Miyang decoction is effective in the treatment of hyperlipidemia,which can improve the clinical symptoms,reduce blood lipids and adverse reactions,better security.Its mechanism may be related to the improvement of serum PPARγ/ANGPTL receptor ligand.

参考文献/References:

[1] 李 勇,谢 坤.防治ASCVD的调脂治疗新靶点:血管生成素样蛋白3[J].临床心血管病杂志,2021,37(9):783-786.
[2] 曹 玲,周 华.血管生成素样蛋白在脂质代谢和心血管疾病中功能和机制的研究进展[J].中西医结合心脑血管病杂志,2021,19(24):4295-4298.
[3] 王静楠,张肖红,郝晓莹.血管生成素样蛋白与胰岛素抵抗和糖代谢的关系及在多囊卵巢综合征中的作用[J].国际生殖健康/计划生育杂志,2022,41(2):160-165.
[4] Mohamed F,Mansfield BS,Raal FJ.ANGPTL3 as a drug target in hyperlipidemia and atherosclerosis[J].Curr Atheroscler Rep,2022,24(12):959-967.
[5] 中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南[J].中国循环杂志,2016,31(10):937-953.
[6] 国家中医药管理局.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:85-89.
[7] 李公豪,赵艳丽,彭中兴,等.下调血管生成素样蛋白7表达对血管紧张素Ⅱ诱导的血管平滑肌细胞增殖和凋亡的影响[J].江苏医药,2022,48(8):761-765.
[8] 蔡 喜,李银萍,王涵钰.血管生成素样蛋白4与经PCI治疗的冠心病患者支架内再狭窄的关系分析[J].检验医学与临床,2022,19(24):3360-3363.
[9] 潘 飞,寿 涓,张冬青.不同他汀类药物治疗非酒精性脂肪性肝病合并高脂血症患者效果分析[J].实用肝脏病杂志,2022,25(5):665-668.
[10] 屈红艳,邢文文,李 璐,等.针灸调节阿尔茨海默病患者线粒体SIRT3机制初探[J].陕西中医,2019,40(2):110-112.
[11] 胡伟婷,李 兴.血管生成素样蛋白6与肥胖及其相关疾病的研究进展[J].国际内分泌代谢杂志,2021,41(3):229-232.
[12] 冯云霞,张维丽,谢沛霖,等.辛温通阳中药葱白提取物对高脂血症模型大鼠线粒体代谢相关限速酶表达的影响[J].中医药学报,2022,50(7):37-41.
[13] 李晓丽,谭华清,唐湘宇.血管生成素样蛋白2与冠心病的研究进展[J].中国心血管病研究,2022,15(4):298-301.
[14] Liu MS,Cui LY,Fan DS,et al.Age at onset of amyotrophic lateral sclerosis in China[J].Acta Neurologica Scandinavica,2014,129(3):163-167.
[15] 张浩然,暴 宇,王 琰,等.血清血管生成素样蛋白6与维持性血液透析患者远期预后的相关性分析[J].国际泌尿系统杂志,2022,42(6):1111-1116.
[16] 陈 鹏,肖晓燕,梅 茜,等.基于仿生技术对薏苡仁麸炒过程中色泽气味变化研究[J].中草药,2022,53(14):4285-4297.
[17] 王天合,李慧君,张丹丹,等.茯苓水提物UPLC指纹图谱的建立及其镇静催眠作用的谱效关系研究[J].中国药房,2021,32(5):564-570.
[18] 张晓慧,刘建东,于峰伟,等.山楂叶总黄酮对急性心肌梗死大鼠心功能的影响及其机制探讨[J].中华心血管病杂志,2021,49(7):701-707.
[19] 兰 卫.洋甘菊总黄酮对高脂血症模型小鼠脂质代谢的影响及机制[J].中国药房,2021,32(22):2706-2712.
[20] 张明昊,高一盈,董文霞,等.复方丹参片对高脂血症模型大鼠血脂水平的改善及肾功能保护作用机制研究[J].中国药房,2022,33(7):818-824.
[21] 于大猛.鹿角胶传统炮制工艺探讨[J].陕西中医,2020,41(6):827-830.
[22] 刘校妃,张志强,邹志琴,等.白参及红参中五种人参皂苷含量的HPLC-MS/MS法快速测定[J].时珍国医国药,2015,26(8):1801-1804.
[23] 黄必胜.阿胶龟胶和鹿角胶中微量元素的测定与分析[J].时珍国医国药,2001,12(6):487.
[24] 郭菊珍,秦亚茹.山药为主治疗婴幼儿非感染性腹泻64例[J].陕西中医,2011,32(7):803.
[25] 刘 暖,杨 雷,毛秉豫.丹参酚酸B调控PKD1-HIF-1α-VEGF通路促心肌梗死大鼠血管新生的作用[J].中国药理学通报,2020,36(7):984-990.
[26] 李 莹,吴莎莎,曹 璨,等.山楂、乌梅、葡萄皮、枸杞、桑葚复方组合物的体内降血脂作用[J].食品工业科技,2022,43(18):365-370.
[27] 何世明.桂枝茯苓合黄连解毒汤对不稳定型心绞痛患者血管内皮功能及血脂水平的影响[J].广西中医药大学学报,2019,22(4):10-12.

相似文献/References:

[1]丁 维,钟立仁,张海波,等.丹参酮ⅡA磺酸钠对高脂血症勃起功能障碍大鼠Nrf2/HO-1通路及勃起功能的影响*[J].陕西中医,2020,(11):1520.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.002]
　DING Wei,ZHONG Liren,ZHANG Haibo,et al.Sodium tanshinone ⅡA sulfonate ameliorates erectile function in hyperlipidemia ED rats by up-regulating Nrf2/HO-1[J].,2020,(11):1520.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.002]
[2]刘小微,李娟娥,姜小帆,等.丹蒌片对载脂蛋白E基因敲除小鼠血脂及AMPK/SREBP通路的影响[J].陕西中医,2021,(11):1531.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.008]
[3]孙帅玲,马晓北.基于网络药理学探讨茵陈蒿汤治疗高脂血症作用机制[J].陕西中医,2021,(12):1793.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.038]
[4]吴巧敏,刘金凤,汪艳丽,等.刘如秀教授论治血浊经验[J].陕西中医,2022,(5):624.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.019]
　WU Qiaomin,LIU Jinfeng,WANG Yanli,et al.Professor LIU Ruxiu's experience in treating hyperlipidemia[J].,2022,(11):624.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.019]
[5]周颖丽,罗 茜,尹紫薇,等.郭志华治疗高脂血症临床经验[J].陕西中医,2023,(6):781.[doi:DOI:10.3969/j.issn.1000-7369.2023.06.023]
　ZHOU Yingli,LUO Xi,YIN Ziwei,et al.Guo Zhihua's clinical experience in the treatment of hyperlipidemia[J].,2023,(11):781.[doi:DOI:10.3969/j.issn.1000-7369.2023.06.023]
[6]刘美之,王俊林,边爱忠,等.从中医痰湿体质论治高脂血症研究进展[J].陕西中医,2024,(5):719.[doi:DOI:10.3969/j.issn.1000-7369.2024.05.034]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助项目(81704061); 湖南省保健专项资金资助科研课题(A2021-06)
更新日期/Last Update: 2023-11-09